EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab

Maeva Ullmann, Katja Seipel iD, Henning Nilius iD, Martina Bertschinger iD, Vera Rentsch, Ulrike Bacher iD, Thomas Pabst iD

Cancers · 13.03.2026 · 18 (6) · 930

DOI: 10.3390/cancers18060930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 13.03.2026. Verfasst von Maeva Ullmann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glofitamab is a bispecific antibody engaging CD3 on T-cells and CD20 on B-cells. Glofitamab is approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (R/R DLBCL). Lymphocyte-activation gene 3 (LAG3) and T-lymphocyte-associated protein 4 (CTLA4) are immune checkpoint receptors with inhibitory effects on T-cell activity. There are several common germline variants of both receptor genes.

Methods

Here, we evaluate clinical outcomes in R/R DLBCL patients treated with glofitamab according to the single-nucleotide polymorphisms LAG3 rs870849 and CTLA4 rs231775.

Results

While there was no apparent association of CTLA4 genotype with glofitamab treatment outcomes, significant differences emerged in LAG3 rs870849 carriers with extended progression-free and overall survival in homozygous LAG3 T455, intermediate PFS and OS in heterozygous LAG3 I455T, and short PFS and OS in homozygous LAG3 I455 carriers.

Conclusions

LAG3 rs870849 may be a prognostic response marker in R/R DLBCL treated with glofitamab.

Schlagwörter

Stichwörter der Autor:innen

T-lymphocyte-associated protein 4 (CTLA4)bispecific T-cell engager (BiTE)bispecific antibody (BsAb)diffuse large B-cell lymphoma (DLBCL)glofitamablymphocyte-activation gene 3 (LAG3)single nucleotide polymorphism (SNP)

Autor:innen und Institutionen

  • Department of Medical Oncology, Inselspital, University of Bern, 3010 Bern, Switzerland.
  • Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
  • Department of Clinical Chemistry, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
  • Department of Hematology, Inselspital, University of Bern, 3010 Bern, Switzerland.

ORCID-Profile: Katja Seipel, Henning Nilius, Martina Bertschinger, Ulrike Bacher, Thomas Pabst

Zitieren

APA

Ullmann, M., Seipel, K., Nilius, H., Bertschinger, M., Rentsch, V., Bacher, U., & Pabst, T. (2026). Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab. Cancers, 18(6), 930. https://doi.org/10.3390/cancers18060930

Vancouver

Ullmann M, Seipel K, Nilius H, Bertschinger M, Rentsch V, Bacher U, et al. Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab. Cancers. 2026;18(6):930. doi:10.3390/cancers18060930

BibTeX
@article{Ullmann2026,
  author = {Ullmann, Maeva and Seipel, Katja and Nilius, Henning and Bertschinger, Martina and Rentsch, Vera and Bacher, Ulrike and Pabst, Thomas},
  title = {Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {930},
  doi = {10.3390/cancers18060930}
}
Kostenlos starten →